ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/YES1-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/YES1-inhibitor
4
trial(s) found.
NCT04925648
Advanced
Phase 2
Recruiting
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (
PICASSO
)
AR-targeted agent,next generation
AR-targeted agent,second generation
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
Darolutamide
Dasatinib
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
cancer therapy
cancer therapy,AR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,SRC-targeting
cancer therapy,YES1-targeting
endocrine therapy
endocrine therapy,androgen axis-targeting
+ YES1 inhibitor
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12623001338651
Haem
Phase 2
Recruiting
CML14 (ASCENDANCE) - ASCiminib Evaluation in Newly diagnosed CML with Dasatinib to Augment response in Complex genomic Etiology (
CML14-ASCENDANCE
)
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
Chronic myelogenous leukaemia
ACTRN12621000611820
Advanced
Phase 2
Recruiting
Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction (
PICAASO
)
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
Dasatinib
KIT inhibitor
PDGFRA inhibitor
SRC inhibitor
YES1 inhibitor
cancer therapy
cancer therapy,BCR-ABL1-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,SRC-targeting
cancer therapy,YES1-targeting
+ YES1 inhibitor
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ YES1 inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Status unknown (1)
Recruitment Country and State
NSW (3)
VIC (2)
Phase
Phase 2 (3)
Trial Type
Advanced (3)
Haem (1)
Cancer Therapy Class
BCR-ABL1
100%
KIT
100%
PDGFRA
100%
SRC
100%
YES1
100%
AR
25%
androgen axis
25%
ALK
25%
ATR
25%
CDK4
25%
CDK6
25%
CRAF
25%
EGFR
25%
FLT3
25%
JAK1
25%
JAK2
25%
MET
25%
PDGFR
25%
PI3K
25%
RAF
25%
ROS1
25%
SMO
25%
VEGFR
25%
mTOR
25%
mTORC1
25%
mTORC2
25%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
Cancer Type
Cancer
Solid tumour
Male genital cancers
Prostate cancer
Urogenital cancer
Chronic leukaemia
Chronic myelogenous leukaemia
Haematological malignancy
Leukaemia
Myeloid leukaemia
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy